Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504023 · ClinicalTrials.gov registry record · NA

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

A NA study of Vulvar Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
NA
Development phase
8
Enrollment target
2
Study locations

NCT00504023: Completed NA study of Vulvar Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00504023 is a NA study of Vulvar Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants, below the 453-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504023, a NA study of Vulvar Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.

Conditions Studied

Interventions

  • PROCEDURE biopsy
  • PROCEDURE therapeutic conventional surgery
  • DRUG imiquimod

Study Locations (2)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Ohio

  • Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2007-04
Est. Completion 2018-01
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00504023

The ClinicalTrials.gov registry entry for NCT00504023 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 453-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vulvar Cancer appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.

NCT00504023 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT00504023 about?

NCT00504023 is a clinical study titled "Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva". RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imi...

What is the current status of trial NCT00504023?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2007-04. Estimated completion is 2018-01.

What conditions does trial NCT00504023 study?

This clinical trial studies the following conditions: Vulvar Cancer.

What interventions are being tested in trial NCT00504023?

The interventions under investigation include: biopsy (PROCEDURE), therapeutic conventional surgery (PROCEDURE), imiquimod (DRUG).

Who is sponsoring clinical trial NCT00504023?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00504023 being conducted?

This trial has 2 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vulvar Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.